An interventional study of Meloxicam and Placebo in Osteoarthritis of the Knee, sponsored by Pfizer. Completed at 25 sites in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-31.
Sponsored by Pfizer · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Osteoarthritis, Knee by Pfizer — 2 open to participants now, 2 under way, 2 of them phase 3. Osteoarthritis, Knee · Pfizer.
Among the 17 studies in Osteoarthritis, Knee by Pfizer, this one is the 8th largest by enrollment, is one of 2 that started in 2011, is the only one with no phase, and was the 11th registered.
3,295 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →2 of the 17 studies in Osteoarthritis, Knee by Pfizer are open now, in 2 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
By country, each count listing its studies:
Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 408 is above the median of 68 across 2,716 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 200 across the 17 interventional studies. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Osteoarthritis, Knee by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is to validate the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) tool in mainland Chinese patients with osteoarthritis of the knee . This study will also evaluate the effects of Mobic versus placebo on reducing the symptoms of osteoarthritis in this population.
To validate culturally the WOMAC tool in mainland China and observe the different response of meloxicam and placebo in a patient population with osteoarthritis of the knee
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects are required to meet the following criteria to be eligible for Randomization into this study:
Exclusion Criteria:
Subjects presenting with any of the following will not be included in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Meloxicam
2 Placebo capsules once a day for 12 weeks
Drug: Placebo
7.5mg x2 once a day for 12 weeks
Also known as: Mobic
Study subjects will be randomized to two treatment groups: one with Meloxicam 7.5 mgx2 once a day and another one with placebo. The duration of the interventional treatment is 12 weeks.
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total and the 3 Subscales Scores (Pain, Stiffness and Physical Function) at Screening 1 by Using a Paper Worksheet and a Personalized Electronic LogPad System (E-diary)
The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. The WOMAC total score was the sum of scores from the 5, 2 and 17 questions respectively on pain, stiffness and physical function subscales. WOMAC total score ranged from 0 to 240, where higher scores indicated worse health condition.
Time frame: Screening 1 (Visit 1: Days -21 to -14)
WOMAC Total and the 3 Subscales Scores (Pain, Stiffness and Physical Function) at Screening 2 by Using E-diary
The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. The WOMAC total score was the sum of scores from the 5, 2 and 17 questions respectively on pain, stiffness and physical function subscales. WOMAC total score ranged from 0 to 240, where higher scores indicated worse health condition.
Time frame: Screening 2 (Visit 2: Days -14 to -10)
WOMAC Total and the 3 Subscales Scores (Pain, Stiffness and Physical Function) at Baseline by Using E-diary
The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. The WOMAC total score was the sum of scores from the 5, 2 and 17 questions respectively on pain, stiffness and physical function subscales. WOMAC total score ranged from 0 to 240, where higher scores indicated worse health condition.
Time frame: Baseline (Day 1)
WOMAC Total and the 3 Subscales Scores (Pain, Stiffness and Physical Function) at Week 12 by Using E-diary
The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. The WOMAC total score was the sum of scores from the 5, 2 and 17 questions respectively on pain, stiffness and physical function subscales. WOMAC total score ranged from 0 to 240, where higher scores indicated worse health condition.
Time frame: Visit 8 (Week 12)
Change From Baseline in WOMAC Pain Subscale Scores at Week 12
WOMAC pain subscale is comprised of 5 questions regarding the amount of pain experienced in the index knee in the past 48 hours. The WOMAC pain subscale scores range from 0 to 10 with higher scores indicating higher pain. The WOMAC pain subscale score was calculated as the mean of the scores from the individual questions.
Time frame: Baseline and Week 12
Change From Baseline in WOMAC Subscale and Average Scores at Weeks 2, 4, 8 and 12
The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. Change from baseline was calculated for each WOMAC subscale (pain, stiffness, physical function) and WOMAC average score.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Change From Baseline in WOMAC Pain Subscale Items at Weeks 2, 4, 8 and 12
WOMAC pain subscale is comprised of 5 questions regarding the amount of pain experienced in the index knee in the past 48 hours. The WOMAC pain subscale scores range from 0 to 10 with higher scores indicating higher pain. Change from baseline in two of the WOMAC pain subscale items: pain when walking on a flat surface, and pain when going up or down stairs were calculated.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Percentage of Participants With Cumulative Reduction From Baseline in WOMAC Pain Subscale at Week 12
WOMAC pain subscale is comprised of 5 questions regarding the amount of pain experienced in the index knee in the past 48 hours. The WOMAC pain subscale scores range from 0 to 10 with higher scores indicating higher pain. The WOMAC pain subscale score was calculated as the mean of the scores from the individual questions. WOMAC pain subscale response rates at Week 12 were shown for the reductions from Baseline of greater than (\>) 0%, 10% to 90% (in steps of 10%).
Time frame: Baseline and Week 12
Percentage of Participants With at Least 30% and 50% Reduction From Baseline in the WOMAC Pain Subscale at Weeks 2, 4, 8, and 12
WOMAC pain subscale is comprised of 5 questions regarding the amount of pain experienced in the index knee in the past 48 hours. The WOMAC pain subscale scores range from 0 to 10 with higher scores indicating higher pain. The WOMAC pain subscale score was calculated as the mean of the scores from the individual questions.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Change From Baseline in Patient Global Assessment of Osteoarthritis (PGAO) at Weeks 2, 4, 8 and 12
PGAO questionnaire ("Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?") was comprised of 5 scores with 1=very good to 5=very poor, where higher grades indicated more effect of osteoarthritis.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Percentage of Participants With >=2 Points Improvement in PGAO From Baseline at Weeks 2, 4, 8, and 12
PGAO questionnaire ("Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?") was comprised of 5 grades with 1=very good to 5=very poor, where higher grades indicated more effect of osteoarthritis. The treatment response of an improvement of \>=2 points from Baseline in PGAO were summarized.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Change From Baseline in Short-Form 36 Health Survey (SF-36) Domain Scores and Component Scores at Week 12
The SF-36 is a self-administered questionnaire that measures each of the following 8 health domains: physical functioning, role limitations due to physical problems (role-physical), social functioning, bodily pain, mental health, role limitations due to emotional problems (role-emotional), vitality, and general health perception. There are also 2 component scores derived from the 8 subscale scores: physical component summary (including physical functioning, role-physical, bodily pain and general health) and mental component summary (including vitality, social functioning, role-emotional and mental health). Each SF-36 domain and component summary score ranges from 0 to 100, higher scores reflect better participant health status.
Time frame: Baseline and Week 12
Percentage of Participants With Change From Baseline in EuroQoL-5 Domains (EQ-5D) Level at Week 12
The EQ-5D is a generic measure of health related quality of life. The EQ-5D has 5 items that assess the level of difficulty (none \[score of 1\], some/moderate \[score of 2\], extreme \[score of 3\]) respondents report for 5 health status domains: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The change from Baseline (decrease by 2, 1, 0, -1 and -2) at Week 12 in each of the 5 health status domains were summarized.
Time frame: Baseline and Week 12
Change From Baseline in Weekly Average Pain Score in the Index Knee Using 11-point Numeric Rating Scale (NRS) at Weeks 2, 4, 8 and 12
Daily average knee pain was assessed with an 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicated worse pain. The participants described their pain in the index knee during the past 24 hours by choosing the appropriate number from 0 to 10.
Time frame: Baseline, Weeks 2, 4, 8 and 12
A total of 24 centers in mainland China recruited study participants, starting from 24 Oct 2011 to 14 Dec 2012.
| Milestone | Placebo | Meloxicam 15 mg |
|---|---|---|
| Started | 146 | 147 |
| Treated | 143 | 144 |
| Completed | 126 | 135 |
| Not completed | 20 | 12 |
| Withdrew: Adverse event | 7 | 3 |
| Withdrew: Entry criteria not met | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Medication error | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 2 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Other | 3 | 3 |
| Withdrew: Randomized, not treated | 3 | 3 |
The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. The WOMAC total score was the sum of scores from the 5, 2 and 17 questions respectively on pain, stiffness and physical function subscales. WOMAC total score ranged from 0 to 240, where higher scores indicated worse health condition.
| units on a scale | OA Participants | Healthy Participants |
|---|---|---|
| Pain subscale (paper worksheet) | 5.7 ± 1.47 | — |
| Stiffness subscale (paper worksheet) | 5.3 ± 1.94 | — |
| Physical function subscale (paper worksheet) | 5.7 ± 1.56 | — |
| Total (paper worksheet) | 135.9 ± 35.59 | — |
| Pain subscale (e-dary) | 5.7 ± 1.47 | 0.1 ± 0.22 |
| Stiffness subscale (e-diary) | 5.3 ± 2.00 | 0.1 ± 0.31 |
| Physical function subscale (e-diary) | 5.7 ± 1.56 | 0.0 ± 0.14 |
| Total (e-diary) | 136.0 ± 35.92 | 0.8 ± 3.66 |
The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. The WOMAC total score was the sum of scores from the 5, 2 and 17 questions respectively on pain, stiffness and physical function subscales. WOMAC total score ranged from 0 to 240, where higher scores indicated worse health condition.
| units on a scale | OA Participants |
|---|---|
| Pain subscale score | 5.6 ± 1.46 |
| Stiffness subscale score | 5.4 ± 1.76 |
| Physical function subscale score | 5.8 ± 1.52 |
| Total score | 136.6 ± 35.38 |
The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. The WOMAC total score was the sum of scores from the 5, 2 and 17 questions respectively on pain, stiffness and physical function subscales. WOMAC total score ranged from 0 to 240, where higher scores indicated worse health condition.
| units on a scale | Placebo | Meloxicam 15 mg |
|---|---|---|
| Pain subscale score | 6.0 ± 1.29 | 6.0 ± 1.32 |
| Stiffness subscale score | 5.7 ± 1.56 | 5.6 ± 1.65 |
| Physical function subscale score | 6.1 ± 1.32 | 6.1 ± 1.22 |
| Total score | 145.0 ± 31.05 | 144.8 ± 29.57 |
The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. The WOMAC total score was the sum of scores from the 5, 2 and 17 questions respectively on pain, stiffness and physical function subscales. WOMAC total score ranged from 0 to 240, where higher scores indicated worse health condition.
| units on a scale | Placebo | Meloxicam 15 mg |
|---|---|---|
| Pain subscale score | 4.4 ± 2.05 | 3.6 ± 1.90 |
| Stiffness subscale score | 4.2 ± 2.26 | 3.5 ± 1.96 |
| Physical function subscale score | 4.5 ± 2.08 | 3.7 ± 1.87 |
| Total score | 106.6 ± 49.70 | 88.7 ± 44.45 |
WOMAC pain subscale is comprised of 5 questions regarding the amount of pain experienced in the index knee in the past 48 hours. The WOMAC pain subscale scores range from 0 to 10 with higher scores indicating higher pain. The WOMAC pain subscale score was calculated as the mean of the scores from the individual questions.
| units on a scale | Placebo | Meloxicam 15 mg |
|---|---|---|
| Change From Baseline in WOMAC Pain Subscale Scores at Week 12 | -1.24 (-1.71 to -0.77) | -2.06 (-2.53 to -1.58) |
The WOMAC has 3 subscales: WOMAC pain subscale, WOMAC stiffness subscale and WOMAC physical function subscale, which are comprised of 5, 2 and 17 questions regarding the amount of pain and stiffness experienced in the index knee, and degree of difficulty in doing daily tasks, respectively in the past 48 hours. The WOMAC subscale scores range from 0 to 10 with higher scores indicating higher pain, more stiffness and worse function respectively for pain, stiffness and physical function subscales. The WOMAC subscale scores were calculated as the mean of the scores from the individual questions. Change from baseline was calculated for each WOMAC subscale (pain, stiffness, physical function) and WOMAC average score.
| units on a scale | Placebo | Meloxicam 15 mg |
|---|---|---|
| Pain subscale (Week 2) | -0.76 (-1.15 to -0.36) | -1.12 (-1.52 to -0.73) |
| Pain subscale (Week 4) | -1.18 (-1.60 to -0.76) | -1.53 (-1.95 to -1.11) |
| Pain subscale (Week 8) | -1.31 (-1.74 to -0.87) | -1.82 (-2.26 to -1.39) |
| Pain subscale (Week 12) | -1.24 (-1.71 to -0.77) | -2.06 (-2.53 to -1.58) |
| Stiffness subscale (Week 2) | -0.78 (-1.16 to -0.39) | -1.11 (-1.49 to -0.72) |
| Stiffness subscale (Week 4) | -1.14 (-1.58 to -0.71) | -1.34 (-1.78 to -0.90) |
| Stiffness subscale (Week 8) | -1.23 (-1.66 to -0.79) | -1.70 (-2.14 to -1.25) |
| Stiffness subscale (Week 12) | -1.20 (-1.67 to -0.72) | -1.86 (-2.34 to -1.39) |
| Physical function subscale (Week 2) | -0.77 (-1.19 to -0.36) | -1.21 (-1.63 to -0.80) |
| Physical function subscale (Week 4) | -1.18 (-1.62 to -0.75) | -1.53 (-1.96 to -1.09) |
| Physical function subscale (Week 8) | -1.31 (-1.74 to -0.88) | -1.82 (-2.26 to -1.38) |
| Physical function subscale (Week 12) | -1.25 (-1.73 to -0.77) | -2.06 (-2.54 to -1.58) |
| Average score (Week 2) | -0.77 (-1.15 to -0.39) | -1.15 (-1.54 to -0.77) |
| Average score (Week 4) | -1.17 (-1.60 to -0.75) | -1.47 (-1.90 to -1.04) |
| Average score (Week 8) | -1.29 (-1.71 to -0.86) | -1.78 (-2.22 to -1.35) |
| Average score (Week 12) | -1.23 (-1.70 to -0.76) | -2.00 (-2.47 to -1.52) |
WOMAC pain subscale is comprised of 5 questions regarding the amount of pain experienced in the index knee in the past 48 hours. The WOMAC pain subscale scores range from 0 to 10 with higher scores indicating higher pain. Change from baseline in two of the WOMAC pain subscale items: pain when walking on a flat surface, and pain when going up or down stairs were calculated.
| units on a scale | Placebo | Meloxicam 15 mg |
|---|---|---|
| Walking on flat surface (Week 2) | -0.51 (-0.92 to -0.10) | -1.13 (-1.54 to -0.71) |
| Walking on flat surface (Week 4) | -1.04 (-1.50 to -0.59) | -1.61 (-2.07 to -1.15) |
| Walking on flat surface (Week 8) | -1.17 (-1.63 to -0.71) | -1.87 (-2.33 to -1.41) |
| Walking on flat surface (Week 12) | -1.05 (-1.53 to -0.56) | -1.97 (-2.46 to -1.48) |
| Going up or down stairs (Week 2) | -1.00 (-1.40 to -0.60) | -1.35 (-1.75 to -0.94) |
| Going up or down stairs (Week 4) | -1.34 (-1.76 to -0.93) | -1.74 (-2.16 to -1.32) |
| Going up or down stairs (Week 8) | -1.53 (-2.00 to -1.07) | -2.09 (-2.55 to -1.62) |
| Going up or down stairs (Week 12) | -1.34 (-1.83 to -0.86) | -2.43 (-2.91 to -1.94) |
WOMAC pain subscale is comprised of 5 questions regarding the amount of pain experienced in the index knee in the past 48 hours. The WOMAC pain subscale scores range from 0 to 10 with higher scores indicating higher pain. The WOMAC pain subscale score was calculated as the mean of the scores from the individual questions. WOMAC pain subscale response rates at Week 12 were shown for the reductions from Baseline of greater than (\>) 0%, 10% to 90% (in steps of 10%).
| percentage of participants | Placebo | Meloxicam 15 mg |
|---|---|---|
| >0% reduction | 53.1 | 75.7 |
| Greater than or equal to (>=) 10% reduction | 46.2 | 67.4 |
| >=20% reduction | 37.1 | 58.3 |
| >=30% reduction | 29.4 | 49.3 |
| >=40% reduction | 22.4 | 43.8 |
| >=50% reduction | 16.1 | 34.0 |
| >=60% reduction | 10.5 | 24.3 |
| >=70% reduction | 7.7 | 12.5 |
| >=80% reduction | 4.2 | 6.3 |
| >=90% reduction | 2.1 | 3.5 |
WOMAC pain subscale is comprised of 5 questions regarding the amount of pain experienced in the index knee in the past 48 hours. The WOMAC pain subscale scores range from 0 to 10 with higher scores indicating higher pain. The WOMAC pain subscale score was calculated as the mean of the scores from the individual questions.
| percentage of participants | Placebo | Meloxicam 15 mg |
|---|---|---|
| >=30% reduction (Week 2) | 17.48 | 22.92 |
| >=30% reduction (Week 4) | 30.07 | 36.81 |
| >=30% reduction (Week 8) | 34.97 | 45.14 |
| >=30% reduction (Week 12) | 29.37 | 49.31 |
| >=50% reduction (Week 2) | 4.90 | 9.03 |
| >=50% reduction (Week 4) | 9.09 | 14.58 |
| >=50% reduction (Week 8) | 13.29 | 24.31 |
| >=50% reduction (Week 12) | 16.08 | 34.03 |
PGAO questionnaire ("Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?") was comprised of 5 scores with 1=very good to 5=very poor, where higher grades indicated more effect of osteoarthritis.
| units on a scale | Placebo | Meloxicam 15 mg |
|---|---|---|
| Week 2 | -0.27 (-0.39 to -0.15) | -0.45 (-0.57 to -0.33) |
| Week 4 | -0.37 (-0.50 to -0.23) | -0.53 (-0.66 to -0.39) |
| Week 8 | -0.34 (-0.46 to -0.23) | -0.52 (-0.64 to -0.40) |
| Week 12 | -0.43 (-0.58 to -0.28) | -0.62 (-0.78 to -0.47) |
PGAO questionnaire ("Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?") was comprised of 5 grades with 1=very good to 5=very poor, where higher grades indicated more effect of osteoarthritis. The treatment response of an improvement of \>=2 points from Baseline in PGAO were summarized.
| percentage of participants | Placebo | Meloxicam 15 mg |
|---|---|---|
| Week 2 | 2.80 | 4.86 |
| Week 4 | 6.29 | 11.81 |
| Week 8 | 5.59 | 6.25 |
| Week 12 | 8.39 | 13.19 |
The SF-36 is a self-administered questionnaire that measures each of the following 8 health domains: physical functioning, role limitations due to physical problems (role-physical), social functioning, bodily pain, mental health, role limitations due to emotional problems (role-emotional), vitality, and general health perception. There are also 2 component scores derived from the 8 subscale scores: physical component summary (including physical functioning, role-physical, bodily pain and general health) and mental component summary (including vitality, social functioning, role-emotional and mental health). Each SF-36 domain and component summary score ranges from 0 to 100, higher scores reflect better participant health status.
| units on a scale | Placebo | Meloxicam 15 mg |
|---|---|---|
| General health | 4.60 (1.93 to 7.28) | 5.98 (3.29 to 8.67) |
| Physical functioning | 6.95 (3.73 to 10.16) | 12.88 (9.65 to 16.12) |
| Role physical | 5.79 (1.74 to 9.84) | 13.95 (9.89 to 18.02) |
| Bodily pain | 7.51 (4.44 to 10.58) | 14.87 (11.78 to 17.96) |
| Vitality | 5.03 (2.56 to 7.50) | 7.08 (4.61 to 9.55) |
| Social functioning | 6.06 (2.60 to 9.51) | 12.02 (8.55 to 15.49) |
| Role emotional | 4.65 (0.26 to 9.04) | 10.52 (6.11 to 14.93) |
| Mental health | 4.50 (2.13 to 6.87) | 5.07 (2.71 to 7.43) |
| Mental component aggregate | 2.19 (0.74 to 3.65) | 3.14 (1.67 to 4.60) |
| Physical component aggregate | 2.65 (1.36 to 3.94) | 5.21 (3.92 to 6.51) |
The EQ-5D is a generic measure of health related quality of life. The EQ-5D has 5 items that assess the level of difficulty (none \[score of 1\], some/moderate \[score of 2\], extreme \[score of 3\]) respondents report for 5 health status domains: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The change from Baseline (decrease by 2, 1, 0, -1 and -2) at Week 12 in each of the 5 health status domains were summarized.
| percentage of participants | Placebo | Meloxicam 15 mg |
|---|---|---|
| Mobility (decrease by 2) | 0 | 0 |
| Mobility (decrease by 1) | 2.8 | 0.7 |
| Mobility (decrease by 0) | 79.7 | 66.0 |
| Mobility (decrease by -1) | 14.0 | 28.5 |
| Mobility (decrease by -2) | 0 | 0 |
| Self-care (decrease by 2) | 0 | 0 |
| Self-care (decrease by 1) | 3.5 | 4.2 |
| Self-care (decrease by 0) | 67.8 | 55.6 |
| Self-care (decrease by -1) | 25.2 | 35.4 |
| Self-care (decrease by -2) | 0 | 0 |
| Usual activities (decrease by 2) | 0 | 0 |
| Usual activities (decrease by 1) | 0.7 | 2.8 |
| Usual activities (decrease by 0) | 81.1 | 63.2 |
| Usual activities (decrease by -1) | 14.7 | 29.2 |
| Usual activities (decrease by -2) | 0 | 0 |
| Pain/discomfort (decrease by 2) | 0 | 0 |
| Pain/discomfort (decrease by 1) | 2.1 | 2.1 |
| Pain/discomfort (decrease by 0) | 77.6 | 67.4 |
| Pain/discomfort (decrease by -1) | 15.4 | 25.0 |
| Pain/discomfort (decrease by -2) | 1.4 | 0.7 |
| Anxiety/depression (decrease by 2) | 0.7 | 0 |
| Anxiety/depression (decrease by 1) | 7.7 | 6.3 |
| Anxiety/depression (decrease by 0) | 72.0 | 67.4 |
| Anxiety/depression (decrease by -1) | 14.7 | 20.8 |
| Anxiety/depression (decrease by -2) | 1.4 | 0.7 |
Daily average knee pain was assessed with an 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicated worse pain. The participants described their pain in the index knee during the past 24 hours by choosing the appropriate number from 0 to 10.
| units on a scale | Placebo | Meloxicam 15 mg |
|---|---|---|
| Week 2 | -0.67 (-1.00 to -0.34) | -0.97 (-1.30 to -0.64) |
| Week 4 | -1.11 (-1.51 to -0.70) | -1.42 (-1.83 to -1.01) |
| Week 8 | -1.31 (-1.78 to -0.85) | -1.76 (-2.22 to -1.29) |
| Week 12 | -1.43 (-1.94 to -0.91) | -2.06 (-2.57 to -1.55) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 2/143 (1.4%) | 0/143 (0%) |
| Meloxicam 15 mg | — | 0/144 (0%) | 0/144 (0%) |
| OA Participants Not Randomized | — | 0/63 (0%) | 0/63 (0%) |
| OA Participants Randomized But Not Treated | — | 0/6 (0%) | 0/6 (0%) |
| Healthy Participants | — | 0/52 (0%) | 0/52 (0%) |
| Event | Placebo | Meloxicam 15 mg | OA Participants Not Randomized | OA Participants Randomized But Not Treated | Healthy Participants |
|---|---|---|---|---|---|
| Angina unstableCardiac disorders | 1/143 | 0/144 | 0/63 | 0/6 | 0/52 |
| AstheniaGeneral disorders | 1/143 | 0/144 | 0/63 | 0/6 | 0/52 |
| Haemoglobin decreasedInvestigations | 1/143 | 0/144 | 0/63 | 0/6 | 0/52 |
| Platelet count decreasedInvestigations | 1/143 | 0/144 | 0/63 | 0/6 | 0/52 |
| Red blood cell count decreasedInvestigations | 1/143 | 0/144 | 0/63 | 0/6 | 0/52 |
| Weight decreasedInvestigations | 1/143 | 0/144 | 0/63 | 0/6 | 0/52 |
| White blood cell count decreasedInvestigations | 1/143 | 0/144 | 0/63 | 0/6 | 0/52 |
| Decreased appetiteMetabolism and nutrition disorders | 1/143 | 0/144 | 0/63 | 0/6 | 0/52 |
| RashSkin and subcutaneous tissue disorders | 1/143 | 0/144 | 0/63 | 0/6 | 0/52 |
Full Analysis Set (FAS): all randomized participants who received at least 1 dose of study medication.
| Age, Customized(Participants) | Placebo | Meloxicam 15 mg | Total |
|---|---|---|---|
| 26 to 35 years | 1 | 1 | 2 |
| 36 to 45 years | 4 | 12 | 16 |
| 46 to 55 years | 43 | 44 | 87 |
| 56 to 65 years | 61 | 60 | 121 |
| 66 to 75 years | 34 | 27 | 61 |
| Sex: Female, Male(Participants) | Placebo | Meloxicam 15 mg | Total |
|---|---|---|---|
| Female | 106 | 122 | 228 |
| Male | 37 | 22 | 59 |
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Oct 2011 to primary completion in Mar 2013, 17 months.
Results were first posted in Dec 2020, 7 years 9 months after primary completion.
Of 140 industry-sponsored interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's 17 months is close to that.
Counting every sponsor, half of 1,251 studies reached it within 18 months; a quarter within 8 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Meloxicam